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Abstract: Eosinophilic asthma is now recognized as an important subphenotype of asthma 
based on the pattern of inflammatory cellular infiltrate in the airway. Eosinophilic asthma can be 
associated with increased asthma severity, atopy, late-onset disease, and steroid refractoriness. 
Induced sputum cell count is the gold standard for identifying eosinophilic inflammation in 
asthma although several noninvasive biomarkers, including fractional exhaled nitric oxide and 
periostin, are emerging as potential surrogates. As novel therapies and biologic agents become 
increasingly available, there is an increased need for specific phenotype-directed treatment 
strategies. Greater recognition and understanding of the unique immunopathology of this 
asthma phenotype has important implications for management of the disease and the potential 
to improve patient outcomes. The present review provides a summary of the clinical features, 
pathogenesis, diagnosis, and management of eosinophilic asthma.
Keywords: asthma, eosinophil, allergy, Th2, IL-4, IL-13 
Introduction
An estimated 8.4% of the US population has a diagnosis of asthma and approxi-
mately 10%–20% of those individuals remain poorly controlled despite high-dose 
inhaled corticosteroids and long-acting beta-agonists.1,2 Asthma has been traditionally 
defined as a chronic respiratory disease characterized by reversible airflow obstruc-
tion, bronchial hyperresponsiveness, and airway inflammation. It is now recognized 
that the term “asthma” actually represents a heterogeneous collection of respiratory 
diseases with distinct phenotypes originating from the complex interplay between 
individual genetic and environmental factors. Therefore, rather than a “one size fits 
all” approach to asthma treatment, evidence is now emerging that unique pathophysio-
logic mechanisms may drive airway inflammation in each subtype of the disease and 
alter the response to conventional therapies. By better identifying asthma phenotypes, 
we may be able to use more targeted therapies, both existing and novel, to achieve 
asthma control in patients who have failed standard treatment.
Phenotype-targeted therapies are especially important for patients with severe 
refractory asthma, who represent less than 10% of all asthmatics, but are responsible 
for a disproportionate share of morbidity and health care costs related to the disease.3 
Several strategies have been proposed to categorize severe asthma phenotypes based 
on characteristics such as patient age, disease onset, corticosteroid resistance, chronic 
airflow obstruction, or type of cellular infiltrate in the airway lumen or lung tissue.4,5 
A newly proposed approach to asthma classification is based on “endotypes” that 
represent specific cellular patterns along with clinical characteristics within each 
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patient subgroup.6 Analysis of induced sputum samples 
has allowed for determination of inflammatory phenotypes 
according to granulocytic composition, namely eosinophilic, 
neutrophilic, mixed granulocytic, or paucigranulocytic.7 
Interestingly, patients with severe adult-onset asthma can 
be divided into a neutrophilic inflammatory phenotype 
or have eosinophilic inflammation that is unresponsive to 
high-dose steroids.8,9 This discussion focuses on our current 
understanding of “eosinophilic asthma” as a distinct asthma 
phenotype in US populations, with special attention paid to 
pathophysiology, diagnostic evaluation, and management.
Eosinophils in the pathogenesis  
of asthma
Eosinophils have long been implicated in the pathogenesis 
of asthma. Post mortem pathologic studies of patients who 
have died from asthma attacks show airway mucosa infiltrated 
with activated eosinophils.10 Over 20 years ago, Bousquet 
et al published their findings demonstrating that chronic 
asthmatics had an increase in eosinophils in peripheral blood 
and bronchoalveolar lavage fluid, along with lung biopsy 
specimens that correlated with the severity of asthma.11 The 
presence of eosinophils in the airway lumen, as identified by 
sputum cell counts, has since been shown to be predictive 
of loss of asthma control after discontinuation of inhaled 
corticosteroids.12,13 Further, the persistence of eosinophils 
in sputum despite high doses of corticosteroids may also be 
a marker of disease severity.14 Generally, the eosinophilic 
phenotype is associated with a good response to corticoster-
oids and to T-helper type 2 (Th2) targeted therapy, such as 
anti-interleukin (IL)-5 treatments discussed below.15–17
Eosinophilic asthma has classically been associated with 
allergic sensitization and a Th2-dominant inflammatory 
response. The Th2-driven phenotype arises from dysregulated 
innate and adaptive immune responses.  During allergic sensi-
tization, inhaled allergens are taken up by antigen-presenting 
dendritic cells in the airway and presented to T-cells.18 The 
cytokine milieu leads to T-helper cell  differentiation and 
production of IL-4, IL-5, and IL-13, resulting in immuno-
globulin (Ig)E class switching, eosinophil recruitment, mucus 
production, airway hyperresponsiveness, and remodeling fea-
tures.19,20 IL-5 is a critical cytokine for eosinophil generation 
in the bone marrow, as well as eosinophil recruitment, activa-
tion, and survival. Upon airway allergen re-exposure, allergen 
cross-linking of IgE on mast cells and basophils results in 
inflammatory degranulation with the release of preformed 
and newly synthesized mediators including histamine, 
cysteinyl leukotrienes, prostaglandin D2, and chemokines, 
resulting in acute allergic reactions with vasodilation, edema, 
and bronchospasm. This is  followed by the influx of activated 
cells, including eosinophils and cytokine-producing T cells 
into the airway, contributing to airway hyperresponsiveness 
that characterizes an asthma exacerbation.
In addition to the classic allergen-mediated Th2 paradigm, 
innate immune stimuli such as environmental factors, air pol-
lution, weather changes (eg, thunderstorms), and viral infec-
tions may be capable of eliciting Th2 responses  associated 
with eosinophilia.21,22 Cytokines derived from bronchial epi-
thelium, including thymic stromal lymphoprotein, IL-25, and 
IL-33, are released in response to an allergen, viral antigen, 
or mucosal injury, and may drive Th2 polarization as well 
as activation of innate type 2 pathways.23 Thymic stromal 
lymphopoietin (TSLP) induced by respiratory syncytial 
virus has been shown to promote a type 2 response to infec-
tion by promoting a dendritic cell/CD4+ Th2 cell activation 
pathway through OX40/OX40 ligand interactions.24,25 TSLP 
also induces dendritic cells to release chemokine ligand 13 
(human monocyte chemoattractant protein-4) and chemokine 
ligand 17 (thymus and activation regulated chemokine), 
which recruit Th2 cells via chemokine receptor 4.26 Other 
cell types including basophils, natural killer T-cells, and 
group 2 innate lymphoid cells are also important sources 
of type 2 cytokines, which regulate eosinophil influx into 
the lungs. Despite the significant complexity of redundant 
and nonredundant inflammatory pathways in asthma, criti-
cal steps that lead to eosinophil influx into the airway have 
been elucidated.
Recruitment of eosinophils into the airway in allergic 
asthma is mediated by the coordinated action of cytokines 
and chemokines including IL-5, IL-13, eotaxins, and the 
adhesion molecules P-selectin and vascular cell adhesion 
molecule-1.27 Maturation of eosinophils from myeloid 
precursors in the bone marrow is promoted by IL-5, IL-3, 
and granulocyte macrophage-colony stimulating factor 
(GM-CSF).28  Eosinophils then circulate in the peripheral 
blood and are normally present in peripheral tissue and 
respiratory mucosa, but increase in number in the setting of 
acute inflammation. IL-5 is a potent eosinophil activator and 
facilitates recruitment into tissues that is further enhanced by 
eotaxins and chemokine ligand 5 (also known as RANTES) 
released by immune and airway resident cells.29  GM-CSF 
is upregulated after allergen challenge and is localized to 
alveolar macrophages and lymphocytes as well as eosino-
phils themselves, suggesting an autocrine pathway.30,31 Other 
chemoattractants for eosinophils include complement product 
C5a and the lipid mediators platelet-activating factor and 
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leukotriene B4. Upon migration from the blood, eosinophils 
bind to endothelial cells expressing E-selectin and vascular 
cell adhesion molecule-1 (ligand for VLA-4 integrin), which 
facilitate migration into the tissue.32 Eosinophil infiltration 
also depends on chemokine ligand 11 (eotaxin-1), which 
is produced by the respiratory epithelium and binds to the 
eosinophil chemokine receptor 3 (CCR3).33
Once activated, eosinophils secrete their granule contents 
which consist of four principal proteins: major basic protein, 
eosinophilic cation protein, eosinophilic-derived neurotoxin, 
and eosinophil peroxidase. Eosinophils also release inflam-
matory lipid mediators, including cysteinyl leukotrienes C4 
and D4, platelet-activating factor, and prostaglandin D2 which 
further propagate the allergic response. Murine models have 
suggested that IL-5 and eosinophils may also promote airway 
remodeling via eosinophil expression of transforming growth 
factor-β.34 Other important growth factors and Th2 cytokines 
that may contribute to airway remodeling in asthma include 
vascular endothelial growth factor, IL-9, and IL-13, which 
may also be produced by eosinophils.20 These pathways along 
with therapeutic targets are highlighted in Figure 1.
Defining eosinophilic asthma
Eosinophilic asthma has been defined as a distinct phenotype 
of asthma that is associated with tissue and sputum eosino-
philia, thickening of the basement membrane zone, and often 
Figure 1 Schematic of eosinophils in airway inflammation and therapeutic targets. In response to allergens, viruses, or mucosal injury, airway epithelial cells produce 
cytokines, including iL-25, iL-33, and TSLP, which promote differentiation of Th2 cells, as well as activation of mast cells, macrophages, and type 2 innate lymphoid 
cells. iL-4 and iL-13 produced by Th2 and other cells results in eotaxin production, B-cell ige class switching, airway hyperresponsiveness, and mucus secretion. iL-5 
stimulates bone marrow eosinophil generation, and mediates recruitment, activation, and survival of eosinophils. GM-CSF produced by alveolar macrophages 
and eosinophils contributes to maturation and survival of eosinophils. Eosinophils release major basic protein, ROS, and enzymes, as well as Th2 cytokines and 
inflammatory lipid mediators including cysteinyl leukotrienes and prostaglandin D2. These products result in recruitment and activation of immune and structural 
cells. Further, production of Th2 cytokines and growth factors, such as TGF-β, contribute to features of airway remodeling in chronic asthma. A number of 
therapeutic targets (depicted by bullseyes) have been identified for eosinophilic asthma and are currently under investigation.
Abbreviations: CRTH2, chemoattractant receptor homologous Th2; CystLTs, cysteinyl leukotrienes; GM-CSF, granulocyte macrophage-colony stimulating factor; iL, 
interleukin; iLC2, innate lymphoid cell type 2; ige, immunoglobulin e; PGD2, prostaglandin D2; ROS, reactive oxygen species; Siglec-8, sialic acid binding ig-like lectin 8; Th2, 
T-helper type 2; TGF-β, transforming growth factor beta; TSLP, thymic stromal lymphoprotein.
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by corticosteroid responsiveness.15,35 The advent of sputum 
induction has allowed for improved classification of airway 
inflammation, identification of asthma phenotypes, and drawing 
associations with other biomarkers.35 Sputum cell counts defin-
ing eosinophilic asthma vary between studies ranging from 1% 
to 3%. Importantly, normalization of induced sputum eosinophil 
counts has also been shown to be an effective strategy for pre-
venting severe asthma exacerbations and hospitalizations, and 
suggests clinical utility in ongoing asthma management.36
In several studies, the number of eosinophils in induced 
sputum has been detected at higher levels in patients with 
more severe asthma.37–39 Woodruff et al demonstrated that the 
percentage of eosinophils in induced sputum was indepen-
dently associated with more severe airflow obstruction and 
methacholine reactivity in over 200 subjects.37 Another study 
stratified asthmatics into four subgroups based on sputum 
inflammatory cell type and observed the highest degree of 
airway hyperresponsiveness to mannitol in the purely eosino-
philic group.39 Although these studies further implicate the 
eosinophil in a subset of severe asthmatics, additional inves-
tigations suggest that there may be a dissociation between 
airway hyperresponsiveness and eosinophilia.40
Early pathologic studies by Wenzel et al led to the 
description of subgroups of severe asthmatics on the basis 
of the presence or absence of eosinophils.8 Miranda et al 
reported that the majority of severe asthmatics had elevated 
airway eosinophils despite chronic treatment with high-
dose oral steroids.41 However, they found that far fewer 
patients who developed asthma early in life demonstrated 
tissue eosinophilia, as compared with the group with late-
onset asthma (36% early-onset versus 63% late-onset). 
 Surprisingly, there was evidence of persistent eosinophilia 
in the late-onset asthmatics despite a lower rate of skin 
prick sensitization. However, in the early onset group, the 
presence of eosinophils on biopsy was associated with an 
increased prevalence of near-fatal events (intubations). 
This study  highlights the association between numbers 
of eosinophils and severity of asthma in patients with 
corticosteroid-refractory disease and suggests discordance 
between atopy and eosinophilic airway disease in a subset 
of patients.
Importantly, ten Brinke et al challenged the notion of 
steroid-refractory eosinophilic asthma in a follow-up study in 
which sputum eosinophils were eliminated in nearly all severe 
asthmatics using high doses of parenteral  triamcinolone.42 
These results suggest that the persistence of eosinophilia 
was more likely due to inadequate therapy rather than a lack 
of steroid response. However, further studies have supported 
an association between sputum eosinophils and severe adult-
onset asthma.9 These individuals are largely nonatopic, yet 
have persistent eosinophilic airway inflammation, further 
supporting a distinct underlying mechanism of eosinophilic 
inflammation apart from allergy.
Notably, eosinophilic asthma is very prevalent in 
 individuals with nonsevere disease. Berry et al studied sub-
jects with mild to moderate asthma and stratified them by the 
presence or absence of eosinophils in their sputum.15 They 
found that subjects with eosinophilia had increased thickness 
of the subepithelial basement membrane zone and improved 
short-term response to treatment with inhaled corticosteroids. 
In addition, they found higher numbers of T-lymphocytes, 
mast cells, and macrophages in the subgroup of subjects with 
severe asthma and eosinophilia.
In support of distinct subtypes of eosinophilic asthma, 
airway infiltration of eosinophils is present in other respi-
ratory conditions, including allergic bronchopulmonary 
aspergillosis, Churg–Strauss syndrome, aspirin-exacer-
bated respiratory disease, and eosinophilic bronchitis. 
 Eosinophilic bronchitis differs from eosinophilic asthma 
in several ways.  Clinically, patients with eosinophilic 
bronchitis have  symptoms of cough, but in contrast with 
asthmatics, have normal lung function and lack airway 
responsiveness.43 Further, although both conditions are 
associated with eosinophilic infiltration in the airways, 
they have distinct immunohistochemical  features. Biopsy 
specimens from patients with asthma, as compared with 
eosinophilic bronchitis, reveal a striking increase in the 
number of mast cells in smooth muscle bundles.44 Further, 
vascular endothelial growth factor levels and airway per-
meability are increased in asthma, but not in eosinophilic 
bronchitis.45 Vascular endothelial growth factor is believed 
to increase vascular permeability, promote angiogenesis, 
and play a role in several aspects of airway remodeling. The 
principal source of vascular endothelial growth factor in the 
airway is not entirely clear, but may include eosinophils, 
macrophages, epithelial cells, and smooth muscle.20 Thus, 
the presence and activity of other inflammatory cells in 
conjunction with eosinophils may underlie a severe asthma 
endotype.
Diagnostic evaluation  
of eosinophilic asthma
Traditional guideline-based treatment decisions in asthma tar-
get symptoms and lung function, but specific therapies target-
ing the underlying inflammatory process may be needed in a 
subset of patients. Sputum eosinophils are an accurate reflection 
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of Th2-dominant mechanisms in uncontrolled asthma, and 
eosinophilic asthma is generally defined by .1%–3% of 
eosinophils. Induced sputum is the most reliable measure of 
inflammatory cell counts although quantitative sputum cell 
counts are difficult to obtain in routine practice and require 
access to specific laboratories with trained personnel. The 
utility of several alternative markers of eosinophilic inflam-
mation are currently being investigated including peripheral 
blood eosinophil counts, fractional exhaled nitric oxide 
(FeNO), serum IgE, and periostin levels.
Peripheral blood eosinophil counts are easily obtained 
and widely available, but lack both specificity and  sensitivity. 
Although few asthmatics may demonstrate an increase in 
blood eosinophils,46 in those asthmatics with peripheral 
eosinophilia, there is a suggested correlation with severity of 
asthma symptoms and an inverse correlation in pulmonary 
function as measured by forced expiratory volume in one 
second (FEV
1
).47 Nonetheless, blood eosinophil counts have 
not been shown to correlate reliably with elevated sputum 
eosinophils in asthma. Hastie et al recently evaluated mul-
tiple variables including exhaled nitric oxide levels, FEV
1
, 
total IgE, and blood eosinophil counts in predicting asthma 
phenotype.48 The authors demonstrated that levels of blood 
eosinophils .300/µL had a positive predictive value of only 
50% in identifying an eosinophilic asthma phenotype based 
on sputum eosinophils of .2%. Further, longitudinal studies 
examining sputum cell counts in consecutive exacerbations 
showed significant heterogeneity in the type of cellular 
inflammation within the same individuals.49 Taken together, 
these findings suggest that peripheral blood eosinophilia 
may be a marker of disease severity in asthma, but does not 
correlate consistently with sputum eosinophilia.
As discussed, eosinophilic asthma can be associated with 
Th2-mediated allergic disease and allergen  sensitization, 
especially in earlier onset disease. Surprisingly, there does 
not appear to be a correlation with total serum IgE, as dem-
onstrated in a study by Good et al in which  bronchoscopy 
was used to assess asthma phenotypes.50 The authors demon-
strated a lack of correlation between total IgE levels and the 
presence of eosinophils in bronchoalveolar lavage fluid or 
biopsy specimens, despite the fact that over 80% of patients 
with evidence of eosinophils had positive skin testing. Thus, 
although IgE levels may be helpful in the diagnosis of allergic 
bronchopulmonary aspergillosis, with features of asthma and 
eosinophilia, the total IgE has little utility in evaluation of 
most patients with asthma.
Nitric oxide is a reactive molecule synthesized by 
nitric oxide synthase expressed on cells within the airway 
 epithelium. FeNO as measured by breath tests is often used 
as a noninvasive marker of airway inflammation in asthma. 
In contrast with bronchoscopy and sputum induction, FeNO 
measurement is rapid, simple, and noninvasive. There is 
growing evidence that FeNO measurement may be useful 
as a clinical tool in managing asthma and guiding therapy; 
however, conflicting studies have resulted in some contro-
versy about the utility of FeNO.51–53 Smith et al studied more 
than 90 asthmatics and found that FeNO was a useful tool in 
stepping down inhaled corticosteroid therapy.54 Tseliou et al 
also demonstrated that FeNO levels .19 parts per billion 
predicted sputum eosinophilia with a sensitivity of 78% 
and a specificity of 73% in patients with moderate to severe 
asthma, some of whom were prednisone-dependent.55 On the 
other hand, Nair et al reported a lack of correlation between 
sputum eosinophil percentages and FeNO levels in patients 
with prednisone-dependent asthma who participated in a 
clinical trial with the anti-IL-5 antibody mepolizumab.17
Periostin is an extracellular matrix protein upregulated 
by IL-13 and has been shown to facilitate allergen-induced 
eosinophil recruitment to the lungs by mediating eosinophil 
adhesion to fibronectin.56 In murine models, periostin-
deficient mice challenged with Aspergillus fumigatus 
 demonstrated a decrease in airway eosinophilia as compared 
with wild-type mice, but no change in tissue lymphocytes 
or neutrophils.56 Further, periostin has been shown to induce 
survival of lung cancer cells through the Akt/PKB pathway, 
and perhaps periostin could promote the survival of eosino-
phils, although this has not been tested.57 Overall, periostin 
has potential as a systemic biomarker for identification of 
airway eosinophilia in asthmatics, possibly due to its role in 
induction of tissue of eosinophilia.
Using a logistic regression model including age, sex, 
body mass index, IgE levels, blood eosinophils, FeNO 
levels, and serum periostin levels in 59 patients with severe 
asthma, Jia et al recently reported that serum periostin 
was the best  predictor of airway eosinophilia.58 A serum 
periostin level .25 ng/mL had a positive predictive value 
of 93% and a negative predictive value of 37% for sputum 
eosinophils (.3%) or tissue eosinophilia. Further, in a recent 
anti-IL-13 treatment study, patients with higher periostin 
levels had greater improvements in FEV
1
 suggesting that 
periostin levels may be predictive of therapeutic response.59 
While the airway epithelium can be stimulated by IL-4 and 
IL-13 to secrete periostin,60 the precise role of periostin 
in asthma is not clear. Apart from a role in eosinophilia, 
animal models suggest that periostin may be involved in 
airway remodeling via transforming growth factor-β and 
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may also have a protective role in  allergen-induced airway 
hyperresponsiveness.61
A recent study by Kulkarni et al evaluated the use of 
eosinophil protein in airway macrophages as a noninvasive 
biomarker of eosinophilic airway inflammation.62 The burden 
of tissue eosinophilia is a balance between the eosinophilic 
influx and clearance by airway macrophages. Therefore, 
they assessed eosinophil protein levels by means of flow 
cytometry, immunofluorescence, and cytoplasmic hue 
change after macrophage ingestion of apoptotic eosino-
phils. They concluded that airway macrophage eosinophil 
protein content was increased in subjects with severe 
asthma and may have clinical utility in predicting ongoing 
eosinophilic  inflammation and success of weaning from 
corticosteroids.
Therapeutics in eosinophilic asthma
Current management of eosinophilic asthma begins with 
standard guideline-based therapy, including inhaled corticos-
teroids and bronchodilators which have been reviewed exten-
sively elsewhere.63 Generally, the presence of eosinophils 
has been associated with responsiveness to corticosteroids 
although some patients with eosinophilic asthma have been 
reported to be “steroid-refractory”. Specific therapeutics 
targeting inflammatory mediators are currently under inves-
tigation in clinical trials for patients who have failed standard 
therapy and remain steroid-dependent or refractory.
Agents targeting  
corticosteroid resistance
Several mechanisms that may account for corticosteroid-
resistant asthma have been reported including activation of 
p38 mitogen-activated protein kinase and inflammatory genes 
regulated through transcription factor nuclear factor-κB.64 
P38 mitogen-activated protein kinase is important in the acti-
vation of GATA3, the master Th2 cytokine transcription fac-
tor.65 Small molecule p38 inhibitors have been demonstrated 
to attenuate asthmatic features in mice.65 However, clinical 
trials in humans for the treatment of inflammatory disease 
have been associated with substantial systemic side effects.66 
Phosphoinositide 3-kinase (PI3K) also regulates inflam-
matory pathways, and activation of the isozyme PI3Kδ by 
oxidative stress may decrease corticosteroid responsiveness 
through reductions in histone deacetylase 2, an enzyme 
targeted by theophylline.67 Other mechanisms for steroid-
refractory asthma may include increased expression of the 
alternatively spliced variant of the glucocorticoid receptor 
and increased production of macrophage migratory inhibitory 
factor, which may block the anti-inflammatory effects of 
corticosteroids.67,68
Biologic therapies
Availability of biologic agents for the treatment of asthma 
began with the approval of an anti-IgE monoclonal 
antibody, omalizumab (Xolair®; Genentech/Novartis, 
Basel,  Switzerland), for the treatment of uncontrolled 
disease. Drugs targeting specific Th2 cytokines, including 
monoclonal antibodies against IL-5 and IL-13, have also 
shown promise in the treatment of refractory eosinophilic 
asthma.69 As data accumulate supporting patient-specific and 
phenotype- directed therapeutic responses, use of these agents 
may reduce the burden of disease for those with refractory 
symptoms despite current treatments. However, the cost of 
such agents may preclude their widespread use, although 
reductions in emergency room visits and hospitalizations 
may outweigh the expense of therapy.
Omalizumab
Omalizumab is a recombinant humanized monoclonal anti-
body (IgG1) that binds to the Fc portion of IgE that recognizes 
its high-affinity receptor (FcεR1) on the surface of mast cells 
and basophils, resulting in receptor downregulation and inhibi-
tion of inflammatory mediator release.70 Several large-scale 
randomized controlled trials now support the therapeutic 
efficacy of subcutaneously administered omalizumab as 
add-on therapy for severe persistent allergic asthma.71–77 
In asthmatic patients inadequately controlled despite high-
dose inhaled corticosteroids and long-acting beta-agonist 
therapy, omalizumab significantly reduced the rate of severe 
exacerbations and emergency visits.71 Data combined from 
seven randomized controlled trials indicated that total IgE was 
the only predictor of response to therapy.78 However, allergic 
sensitization to aeroallergens by skin prick testing was a key 
inclusion criterion in several of these studies.71–74
IgE has a central role in the pathophysiology of allergic 
responses and omalizumab attenuates both the early-phase 
and late-phase responses to inhaled allergens in patients 
with asthma.79 While total serum IgE levels do not corre-
late diagnostically with the degree of tissue eosinophilia, 
treatment with anti-IgE therapy has been shown to be effi-
cacious and reduce airway and blood eosinophils.80–82 One 
of the initial studies in asthmatics treated with omalizumab 
demonstrated a significant reduction in eosinophils in 
induced sputum and airway tissue (8.0 at baseline compared 
with 1.5 post-treatment).82 A later report showed that 16 
weeks of treatment decreased blood eosinophils from 6.2% 
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at baseline to 1.3%.81 Therefore, while total serum IgE is 
not useful as a diagnostic marker for eosinophilic asthma, 
total serum IgE levels should be obtained if considering 
anti-IgE therapy.
One explanation for the apparent paradox that anti-
IgE therapy is useful for treatment in eosinophilic asthma 
despite IgE levels not being predictive of response may be 
related to downregulation of FcεR1 on the surface of mast 
cells, basophils, and dendritic cells by anti-IgE. A reduc-
tion in FcεR1-expressing cells limits allergen-induced 
IgE- mediated responses, preventing cytokine release and 
eosinophil  recruitment into the airway.83 Additionally, 
treatment with anti-IgE may lead to decreased levels of 
airway dendritic cells84 resulting in a reduction in Th2 dif-
ferentiation and the Th2 cytokines necessary for survival 
and recruitment of eosinophils. Therefore, while total 
serum IgE may not be predictive of eosinophilic asthma or 
clinical response, omalizumab has been shown to have an 
important role in asthma management and reduces airway 
eosinophils.
Interestingly, Noga et al have demonstrated that omali-
zumab may also have proapoptotic effects on eosinophils.79 
In a study of 19 patients with allergic asthma, markers 
of eosinophil apoptosis (Annexin V) were significantly 
increased in patients who had received 12 weeks of omali-
zumab as compared with placebo. The authors also showed a 
reduction in IL-2, IL-13, and GM-CSF+ lymphocytes in the 
omalizumab group. Reduction in levels of mast cell media-
tors that promote eosinophil survival may have led to the 
apoptosis of eosinophils in omalizumab-treated individuals. 
Notably, omalizumab has also been found to be a steroid-
sparing agent in chronic eosinophilic pneumonia, a disease 
characterized by bilateral pulmonary infiltrates and marked 
accumulation of eosinophils in bronchoalveolar lavage fluid 
and blood.85 Thus, the effects of anti-IgE therapy on lung 
eosinophilia have provided further insight into the mecha-
nisms of allergic inflammation, which may lead to improved 
phenotype-specific treatment.
Targeting iL-5
IL-5 plays a critical role in promoting eosinophil growth, 
differentiation, recruitment, and activation in tissues. Early 
reports demonstrated increased expression of IL-5 in bron-
choalveolar lavage fluid and bronchial biopsies from patients 
with asthma.86 Additionally, IL-5 messenger RNA (mRNA) 
was shown to be upregulated in the bronchial mucosa after 
allergen challenge, and levels correlated with disease activ-
ity.87 In animal models, airway eosinophil recruitment and 
airway hyperresponsiveness in response to allergen chal-
lenge were reduced after anti-IL-5 treatment.88 Thus, there 
is ample rationale for targeting IL-5 in human asthma to 
specifically reduce eosinophil maturation, migration, and 
survival, which may contribute to multiple aspects of the 
pathogenesis of asthma.
Mepolizumab is a humanized noncomplement-fixing 
monoclonal antibody (IgG1) specific for human IL-5.89 
Mepolizumab blocks the binding of human IL-5 to the 
alpha chain of the IL-5 receptor complex expressed on the 
eosinophil cell surface with high affinity. Anti-IL5 therapy 
has been shown to induce maturational arrest of bone mar-
row eosinophil precursors and decrease CD34+IL-5Rα+ 
eosinophil progenitors in the bronchial mucosa of atopic 
individuals.90
Early studies examining mepolizumab in the treatment 
of asthma were somewhat disappointing because they 
failed to show a significant effect on airway hyperrespon-
siveness or a late asthmatic reaction after inhaled allergen 
challenge.91–93 These studies may have failed to show a 
meaningful treatment effect due to the endpoints not being 
closely associated with eosinophilic airway inflammation 
as well as the broad inclusion of a heterogeneous study 
population. Despite this, the early studies did show that a 
single dose of anti-IL5 decreased blood eosinophils for up 
to 16 weeks and sputum eosinophils for up to 4 weeks.92 
Of interest, mepolizumab appears to have a differential 
effect in various tissues, with nearly complete reduction 
in blood and sputum eosinophils, but only 55% reduction 
in bronchial mucosa.93 Flood-Page et al postulated that 
varying degrees of tissue penetration, altered IL-5 receptor 
expression, or downregulation could be responsible for these 
differences.93 It is also possible that once recruited into the 
tissue, airway eosinophils may rely on eotaxins, GM-CSF, 
or IL-3 for their survival.
Two recent studies suggest that there may be a benefi-
cial effect of mepolizumab in specific groups of patients 
with eosinophilic asthma. In a double-blind, placebo-
controlled study of 61 subjects with refractory eosinophilic 
asthma and a history of recurrent severe exacerbations, 
 mepolizumab-treated patients showed a significant reduc-
tion in exacerbations, as well as improvement in symptom 
scores after monthly infusions of mepolizumab for one year.16 
A study by Nair et al enrolled asthmatic patients with per-
sistent sputum eosinophilia despite systemic treatment with 
prednisone.17 The authors showed that monthly intravenous 
mepolizumab reduced sputum and blood eosinophilia, and 
had a steroid-sparing effect with a substantial decrease in 
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prednisone use in the treatment group. Anti-IL5 therapy also 
resulted in improved asthma control, FEV
1
, and  quality of 
life. Importantly, these improvements were maintained for at 
least 8 weeks after the last infusion. Thus, targeting specific 
subsets of asthmatics with eosinophilia appears to hold the 
most promise for anti-IL-5 treatment.
Reslizumab, an IgG4 humanized monoclonal antibody 
against IL-5, has also been given to patients with poorly 
controlled eosinophilic asthma.94 A recent study showed a 
 significant reduction in sputum eosinophils and improve-
ment in lung function when compared with placebo after 15 
weeks of treatment with reslizumab 3 mg/kg given at monthly 
intervals. There was also a trend towards a decrease in exacer-
bations, but the study failed to show improvement in asthma 
control (as measured by the Asthma Control Questionnaire). 
The beneficial effects of reslizumab were most pronounced 
in a subgroup of patients with nasal polyps and in those 
with the highest levels of blood and sputum eosinophils. 
 Interestingly, in addition to eosinophil levels, the presence of 
nasal polyposis may identify asthmatic patients who benefit 
the most from anti-IL-5 therapy, although studies designed 
to investigate this further are needed.
Lastly, benralizumab is a humanized afucosylated mono-
clonal antibody targeted against IL-5Rα on eosinophils and 
is currently in Phase II trials. An open Phase I trial in 2010 
enrolled 44 subjects with mild asthma to determine safety and 
effective dosing.95 The primary outcome was met at all doses 
administered with a reduction in blood eosinophil counts 
to nearly undetectable levels (approximately 10 cells/mL) 
within 24 hours. This effect persisted for at least 2–3 months 
in subjects dosed in the 0.03–3 mg/kg range. In a follow-up 
Phase II study, Laviolette et al examined the effect of a single 
1 mg/kg dose of benralizumab given intravenously compared 
with three monthly subcutaneous doses (100 mg or 200 mg) 
or placebo in adults with eosinophilic asthma.96 The authors 
demonstrated that the intravenous and subcutaneous routes 
led to a reduction in eosinophil counts in the airway mucosa 
and sputum, and nearly complete suppression of eosinophil 
counts in bone marrow and peripheral blood for up to 28 days 
after the final dose of benralizumab.  Anti-IL-5 therapies 
undoubtedly hold promise for the treatment of eosinophilic 
severe asthmatics especially as both approved treatments as 
well as routine diagnostics to appropriately identify patients 
become available.
Targeting iL-4 and iL4Rα
IL-4 and IL-13 expressed by Th2 cells, mast cells, baso-
phils, and innate lymphoid cells are key cytokines in the 
pathogenesis of allergic asthma and atopic disease. IL-4 is 
responsible for many features of asthma, including Th2 dif-
ferentiation, mucus production, and B cell isotype switching. 
Both IL-4 and IL-13 signal through two different but over-
lapping heterodimeric receptors that share the alpha subunit 
of the IL-4 receptor (IL-4Rα).97 Receptor ligation activates 
a common signal transducer and activator of transcription 
6 (STAT-6)-mediated signaling pathway critical to devel-
opment of the Th2 inflammation characteristic of asthma. 
Importantly, eotaxins that promote eosinophilic recruitment 
also depend on IL-4/IL-13 activation of STAT6. Several 
drugs are now under investigation targeting the IL-4/IL-13/
STAT6 pathway.
The humanized IL-4 monoclonal antibody pascolizumab 
has been evaluated in animal studies and Phase I/II trials. 
In a Phase I trial, pascolizumab was well tolerated in adult 
patients with mild to moderate asthma; however, a subse-
quent large-scale Phase II trial was discontinued because it 
failed to show clinical effects in symptomatic patients who 
were steroid-naïve.98 Altrakincept is a recombinant human 
IL-4Rα antagonist, and inhibited airway eosinophilic infil-
tration and mucus hypersecretion when administered during 
allergen challenges in a mouse model.99 In a Phase I/II trial, 
a single inhalation of the drug improved lung function and 
asthma symptoms.100 Pitrakinra is an antagonist targeting the 
IL-4/IL-13 cytokine heterodimeric receptor, composed of 
IL-13Rα1 and IL-4Rα subunits. When administered by the 
subcutaneous or inhaled route, pitrakinra inhibited allergen-
induced early-phase and late-phase reactions.101
Dupilumab, a humanized monoclonal antibody to the 
IL-4Rα subunit, was recently studied by Wenzel et al in 
a double-blind, placebo-controlled study.102 The study 
enrolled 104 patients with moderate to severe persistent 
asthma and eosinophilia who were randomized to receive 
dupilumab 300 mg or placebo subcutaneously once weekly 
for 12 weeks. The study found a significant improvement 
in lung function in the treatment group, with an associ-
ated reduction in asthma exacerbations when long-acting 
beta-agonists and inhaled glucocorticoids were withdrawn. 
 Additional findings included significant changes from 
baseline in  Th2-associated biomarkers, including FeNO, 
chemokine ligand 17 (thymus and activation regulated 
chemokine), IgE, and chemokine ligand 26 (eotaxin-3) 
in the dupilumab group at 12 weeks. Blood and sputum 
eosinophil levels were no different after dupilumab treat-
ment, although there were limited numbers of patients 
who provided sputum, thus precluding statistical analysis. 
Overall, targeting IL-4R alpha signaling (which also affects 
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IL-13 signaling) appears to be a promising therapeutic 
strategy in eosinophilic asthma.
Targeting iL-13
In mouse models, IL-13 plays a critical role in eosinophil 
recruitment into the airway in a manner dependent on the 
synergistic activity of eotaxin and IL-5.103 Further, several 
studies suggest that IL-13 may be responsible for glucocor-
ticoid resistance in asthma.104 Animal models using IL-13 
 blockade strategies have shown reductions in allergen-
 induced inflammation, airway hyperresponsiveness, and 
airway remodeling.105,106 Therefore, pharmaceuticals targeting 
this cytokine are currently under investigation in patients with 
steroid-refractory eosinophilic asthma. A Phase II clinical 
trial of anrukinzumab, a fully human IL-13 targeted antibody, 
carried out in mild atopic asthmatics showed a reduction in 
allergen-induced late asthmatic responses after subcutane-
ous administration of two doses (2 mg/kg) separated by 2 
weeks.107
A recent study evaluated lebrikizumab, a humanized 
anti-IL-13 monoclonal antibody, in 219 adults with inad-
equately controlled asthma despite inhaled corticosteroids 
and long-acting beta-agonists.59 The study results showed 
improvement in FEV
1
 in the treatment arm after 12 weeks 
of therapy, with a more pronounced effect in patients with 
high pretreatment serum periostin levels. Interestingly, in 
post hoc analysis, elevated FeNO as well as high Th2 mark-
ers including peripheral eosinophilia, total IgE, chemokine 
ligand 13 (human monocyte chemoattractant protein-4) 
and chemokine ligand 17 (thymus and activation regulated 
chemokine) levels were also associated with a greater reduc-
tion in rates of severe exacerbations in the lebrikizumab 
group compared with placebo. Another anti-IL-13 antibody, 
tralokinumab, has also shown efficacy in improving lung 
function in a Phase II study of patients with moderate to 
severe asthma.108
Other therapies
Other agents under investigation for the treatment of asthma 
include antagonists targeting thymic stromal lymphoprotein, 
IL-25, IL-33, GM-CSF, and chemokine receptor 3 expressed 
on eosinophils.63 Neutralizing  antibodies to the innate 
cytokines IL-25, IL-33, and thymic stromal lymphoprotein 
demonstrate the ability to attenuate allergic airway inflam-
mation in mice,109–111 and antibodies targeting thymic stromal 
lymphoprotein are currently in development as intravenous 
therapy for patients with mild atopic asthma (ClinicalTri-
als.gov identifier: NCT01405963).112 Additionally, inhaled 
antisense oligonucleotides that block the common beta 
chain of IL-3, IL-5, and GM-CSF receptors together with 
chemokine receptor 3 have shown a small overall effect in 
reducing the allergen-induced inflammatory response.113 Fur-
ther, a human monoclonal antibody targeting GM-CSF shown 
to decrease the survival and activation of eosinophils, is cur-
rently in Phase II trials for patients with moderate to severe 
asthma inadequately controlled by corticosteroids.63,114
Therapies targeting inflammatory lipid mediators such 
as prostaglandin D2, which binds to CRTH2 (chemoat-
tractant homologous receptor expressed on Th2 cells) are 
also in clinical development. Several studies evaluating the 
ability of CRTH2 antagonists to block the chemotactic effect 
of prostaglandin D2 on Th2 cells and eosinophils are now 
underway.63 Induction of eosinophilic apoptosis through 
the Siglec-8 (sialic acid binding Ig-like lectin 8) recep-
tor by an activating antibody or glycan ligand-conjugated 
nanoparticles is also a potential therapeutic strategy under 
 investigation.115 Finally, it is worth mentioning that therapies 
blocking tumor necrosis factor-α, including etanercept, inf-
liximab, and golimumab, have so far demonstrated mixed 
results in the treatment of asthma.116,117
Finally, bronchial thermoplasty, which applies thermal 
energy to the bronchial wall to reduce airway smooth muscle 
hypertrophy, has recently been studied as a potential treat-
ment in severe asthma.118 Large clinical trials have showed 
somewhat mixed results, with small improvements in asthma-
specific quality of life measures and exacerbation rates but 
an overall increase in hospitalizations.119 It is unclear exactly 
how this procedure affects the structural airways or the release 
of inflammatory mediators by airway smooth muscle cells, 
and this procedure has not been specifically evaluated in 
patients with eosinophilic asthma or other phenotypes.120
Summary
In summary, identif ication of specif ic phenotypes of 
asthma with unique underlying pathophysiologic mecha-
nisms may be particularly important for the treatment of 
patients with severe asthma. One proposed classification 
based on  distinct patterns of inflammatory cell infiltrate in 
the airway distinguishes eosinophilic from noneosinophilic 
subgroups. Traditionally, airway eosinophilic infiltration 
has been associated with Th2-mediated allergic asthma, 
but there is now evidence that eosinophils are present in the 
airways of severe asthmatics without allergic disease. The 
emergence of novel biologic treatments, including mono-
clonal antibodies and small molecule inhibitors targeted 
against IgE, Th2 cytokines, and specific inflammatory 
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mediators, has led to an enhanced understanding of the 
pathogenesis of asthma and highlighted the importance 
of patient-specific treatment. Development of noninva-
sive biomarkers is becoming increasingly important for 
subsets of asthmatic patients, including those with eosino-
philic inflammation, as they may predict the response to 
therapy.
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